Nasdaq-listed BeiGene expects to need more CMO services for its clinical stage biologics following on from a clinical trials manufacturing agreement for a PD-1 antibody with Boehringer Ingelheim China, which marked the first such pilot program under China’s drug marketing authorization holder system. Shanghai is also preparing risk guarantee funds to back the pilot program, in order to promote pharmaceutical innovation.
SHANGHAI - With the support of the government, Boehringer Ingelheim GMBH‘s China Biopharmaceuticals site has kicked off its first trial contract manufacturing organization (CMO) project, for an oncology drug developed byBeiGene (Beijing) Co. Ltd.
Newly US Nasdaq-listed BeiGene will consider expanding its cooperation with the site for other biopharmaceutical products. “The first trial product...
Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.
